Regenerative modulators use in the surgical treatment of anterior abdominal wall hernias

Hernias of the anterior abdominal wall remain a significant challenge in surgery due to the high rate of postoperative complications. One promising approach to improving patient outcomes involves the use of regeneration modulators, such as pyrimidine derivatives. This article examines the mechanisms of action and clinical potential of pyrimidine-based drugs, including hydroxyethyldimethyldihydropyrimidine (xymedon), in hernioplasty. Key points. Pyrimidine derivatives, including xymedon, offer a broad range of pharmacological effects, such as wound-healing, anti-inflammatory, and immunostimulatory properties. Xymedon has been shown to reduce levels of inflammatory cytokines and acute-phase proteins, enhance tissue proliferation and angiogenesis, and regulate collagen synthesis. Clinical studies indicate that using xymedon following prosthetic hernioplasty decreases the incidence of complications (e.g., seroma and hematoma) and promotes improved wound healing. Conclusion. Regeneration modulators, particularly xymedon, show promise in the surgical treatment of anterior abdominal wall hernias by optimizing the interaction between implants and surrounding tissues. These agents mitigate inflammatory responses, expedite regenerative processes, and enhance tissue resistance to infections. Further research is warranted to refine their clinical applications and broaden their indications.